NEO NeoGenomics, Inc.
NeoGenomics, Inc. operates in the Services-Testing Laboratories industry.
On the WireNo stories on NEO yet. Follow the company and the next one lands in Following.
The numbers · FY2025, filed
SEC EDGARAll filed figures
Snapshot
SEC EDGAR · FY 2025-12-31Revenue by fiscal year
Operating leverage — margins
Financials, annual · income and cash flowSEC EDGAR · open ▸
Financials — annual
SEC EDGAR · last 5 FY · tap a row to explain it| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $484.3M | $509.7M | $591.6M | $660.6M | $727.3M |
| Gross Profit | $187.1M | $187.9M | $244.6M | $290.1M | $314.3M |
| Operating Income | $-118.8M | $-157.6M | $-107.7M | $-92.1M | $-115.9M |
| Net Income | $-8.0M | $-144.0M | $-88.0M | $-79.0M | $-108.0M |
| Diluted EPS | — | — | — | — | — |
| Operating Cash Flow | $-26.7M | $-66.0M | $-2.0M | $7.0M | $5.2M |
| Free Cash Flow | $-90.9M | $-96.9M | $-30.7M | $-34.0M | $-21.8M |
Same industry
In the screener →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.